Mineralys Therapeutics Lorundrostat August 2024 Presentation

Mineralys Therapeutics presents lorundrostat, a selective aldosterone synthase inhibitor targeting hypertension, chronic kidney disease, and heart failure. The clinical-stage biotech company reports proof-of-concept data demonstrating substantial blood pressure reduction and announces pivotal trial programs with readouts expected in 2025.